Page last updated: 2024-08-21

pyrazines and gilteritinib

pyrazines has been researched along with gilteritinib in 101 studies

Research

Studies (101)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	26 (25.74)	24.3611
2020's	75 (74.26)	2.80

Authors

Authors	Studies
Thom, C	1
Stein, EM	1
Hernandez, D; Lee, LY; Levis, M; Nguyen, B; Rajkhowa, T; Raman, JR; Small, D; Smith, SC	1
Kaneko, N; Kuromitsu, S; Mori, K; Mori, M; Saito, R; Shimada, I; Tanaka, R; Ueno, Y; Yamada, M	1
Altman, JK; Baer, MR; Bahceci, E; Claxton, D; Cortes, J; Erba, HP; Gill, S; Goldberg, S; Jurcic, JG; Larson, RA; Levis, M; Litzow, M; Liu, C; Martinelli, G; Neubauer, A; Perl, AE; Ritchie, E; Röllig, C; Schiller, G; Smith, C; Spira, AI; Strickland, SA; Stuart, R; Tibes, R; Ustun, C; Wang, ES	1
Sheridan, C	1
Burthem, J; Gorcea, CM; Tholouli, E	1
Bahceci, E; Iida, H; Kaneko, M; Kobayashi, Y; Kusano, M; Miyamoto, T; Miyawaki, S; Morita, S; Naoe, T; Sakura, T; Takeshita, S; Usuki, K; Yamada, S	1
Ai, J; Dai, Y; Gu, W; Ji, Y; Song, Z; Wang, Y; Xing, L; Ye, J	1
Dhillon, S	1
Tiong, IS; Wei, AH	1
Canaani, J; Carroll, M; McMahon, CM; Morrissette, JJD; Perl, AE; Qualtieri, JN; Rea, B; Sargent, RL; Watt, CD	1
Perl, AE	2
Bixby, DL; Marini, BL; Perissinotti, AJ; Weis, TM	1
Estey, EH; Percival, MM	1
Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J	1
Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Lin, H; Ma, J; Polin, L; Qiao, X; Taub, JW; Wang, G; Wang, Y; White, K; Zhao, L; Zhao, S	1
Saleh, N	1
Eskazan, AE; Kucukyurt, S	1
Akahane, D; Fujimoto, H; Gotoh, A; Katagiri, S; Moriyama, M; Yoshizawa, S	1
Baer, MR; Bahceci, E; Berman, E; Chou, WC; Ciceri, F; Cortes, JE; Di Stasi, A; Erba, HP; Fabbiano, F; Fathi, AT; Hasabou, N; Hosono, N; Kasner, M; Larson, RA; Lee, JH; Levis, MJ; Liu, C; Liu, X; Martinelli, G; Montesinos, P; Neubauer, A; Olin, R; Paolini, S; Pardee, T; Perl, AE; Podoltsev, N; Recher, C; Stuart, R; Ustun, C; Yokoyama, H; Yoon, SS	1
Sidaway, P	1
DiNardo, CD; Wei, AH	1
Hussain, MJ; Katz, DA; Larson, M; Miller, I; Nathan, S; Ustun, C; Varma, A; Yun, HD	1
Rowe, JM	1
Smith, CC	1
Li, L; Li, M; Li, W; Lin, L	1
Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK	1
Cerella, C; Christov, C; Diederich, M; Ha, YN; Kijjoa, A; Orlikova-Boyer, B; Song, S	1
Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J	1
Bahceci, E; Hill, JE; Mori, K; Perl, AE; Rahmat, L; Smith, CC; Tarver, TC	1
Lam, SSY; Leung, AYH	1
Burnett, A; Stone, R	1
Aas, IB; Bolstad, B; Dalhus, ML; Enzmann, H; Gisselbrecht, C; Håkonsen, GD; Karpova, N; Lindberg, V; Nilssen, LS; Olsen, HH; Pignatti, F; Rogovska, I; Røshol, H; Tzogani, K; Økvist, M	1
Kim, RS; Shields, CL; Wilde, LR; Yaghy, A	1
Chishaki, R; Ito, T; Kida, M; Kido, M; Kuraoka, K; Kuroda, Y	1
Ando, T; Katsuya, H; Kidoguchi, K; Kimura, S; Kojima, K; Kubota, Y; Kusaba, K; Sano, H; Yamaguchi, K; Yokoo, M; Yoshihara, S	1
Levis, M; Perl, AE	1
Altman, JK; Bahceci, E; James, AJ; Kadokura, T; Levis, MJ; Litzow, M; Liu, C; Lu, Z; Moy, S; Patton, M; Perl, AE; Shepard, D; Smith, CC; Souda, K	1
Elsarrag, RZ; K Keng, M; Pierce, EJ; Reed, DR; Sen, JM	1
Han, H; Hong, J; Kim, D; Kim, H; Koh, Y; Lee, C; Shin, DY; Yoon, SS	1
Arakawa, Y; Fukuoka, K; Hiraki, T; Inoue, K; Isobe, K; Koh, K; Mitani, Y; Mori, M; Noguchi, J; Oshima, K; Sugawa, M; Takaki, T; Tomita, O; Tsumura, Y; Yanagi, M	1
Chen, D; Chen, Z; Wang, Q; Ye, XY	1
Andrews, C; Maze, D; Murphy, T; Sibai, H	1
Naoe, T	1
Baker, R; Chavda, N; Clark, F; Fielding, AK; Gupta, R; Khwaja, A; Kottaridis, P; Mansour, MR; O'Nions, J; Payne, E; Subhan, M; Thomson, K; Troy-Barnes, E; Wilson, AJ	1
Dutta, R; Jeng, MY; Mannis, GN; Tan, IT; Zhang, TY	1
Bever, GJ; Haq, Z; Liu, Y; Pasricha, ND	1
Blair, HA; Kang, C	1
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM	1
Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC	1
Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A	1
Beaver, L; Blachly, JS; Brinton, LT; Byrd, JC; Canfield, D; Cannon, M; Cempre, C; Govande, M; Harrington, B; Lapalombella, R; Lehman, A; Orwick, S; Sher, S; Skinner, J; Wasmuth, R; Williams, K; Zhang, P	1
Myers, R; Tollkuci, E; Tran, T	1
Fleischmann, M; Heidel, FH; Schnetzke, U; Scholl, S	1
Dobashi, N; Fukushima, R; Gunji, T; Hattori, D; Ishii, H; Ishii, S; Kamitani, I; Katsube, A; Nakano, A; Nishiwaki, K; Oshima, S; Saito, T; Shimada, T; Tanoue, S; Yano, S; Yokoyama, H	1
Hidaka, K; Mori, M	1
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N	1
Fujisawa, S; Harada, S; Izumiyama, K; Kondo, T; Mori, A; Morioka, M; Ogasawara, R; Onozawa, M; Saito, M; Teshima, T	1
De Claro, RA; Farrell, AT; Fu, W; Goldberg, KB; Gudi, R; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Przepiorka, D; Pulte, ED; Qosa, H; Wang, Y; Xu, Q	1
Bottomly, D; Druker, BJ; Joshi, SK; McWeeney, SK; Pittsenbarger, J; Sharzehi, S; Tognon, CE; Traer, E	1
Iwai, F; Kato-Ogura, A; Onaka, T; Otsuka, Y; Yonezawa, A	1
Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G	1
Aleissa, MM; Alshehri, BS; Gonzalez-Bocco, IH; Leblebjian, H; Luskin, MR; Marty, FM; McDonnell, AM	1
Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Li, J; Lin, H; Ma, J; Polin, L; Qiao, X; Su, Y; Taub, JW; Wang, G; Wang, J; Wang, L; Wang, Y; White, K	1
Arshad, OA; Babur, O; Bottomly, D; Cendali, F; D'Alessandro, A; Demir, E; Druker, BJ; Fillmore, TL; Gosline, SJC; Gritsenko, MA; Hansen, JR; Hutchinson, C; Joshi, SK; Kaempf, A; Liu, T; McDermott, JE; McWeeney, SK; Moon, J; Nechiporuk, T; Piehowski, PD; Pittsenbarger, J; Reisz, JA; Rodland, KD; Schepmoes, AA; Shi, T; Tognon, CE; Traer, E; Tsai, CF; Tyner, JW; Wang, YT; Watanabe-Smith, K; Weitz, KK	1
Abematsu, T; Iijima-Yamashita, Y; Inaba, Y; Kawano, Y; Kodama, Y; Nakagawa, S; Nishikawa, T; Okamoto, Y; Shiba, N; Takahashi, Y	1
Baker, SD; Garrison, DA; Jin, Y; Sparreboom, A; Uddin, ME	1
Bidet, A; Desplat, V; Dumas, PY; El-Habhab, A; Fernandez, S; Guitart, AV; Leguay, T; Mansier, O; Martineau, D; Massara, L; Pasquet, JM; Pigneux, A; Vigon, I; Villacreces, A	1
Cimino, G; Cipollone, E; Ortu La Barbera, E; Ottone, T; Perrone, S; Scerpa, MC; Siniscalchi, R; Viola, F; Voso, MT	1
Cuglievan, B; Daver, N; DiNardo, C; Kadia, TM; Mahadeo, KM; McCall, D; Nunez, C; Roth, M; Short, NJ; Toepfer, L; Yi, JS	1
Baker, SD; Buelow, DR; Campbell, MJ; Jeon, JY; Pabla, N; Silvaroli, J; Sparreboom, A; Talebi, Z; Zavorka Thomas, ME	1
Garnham, A; Pandya, BJ; Qi, CZ; Shah, MV; Yang, H; Zeidan, AM	1
Jakubik, M; Jastrzębski, K; Kozik, K; Miączyńska, M; Poświata, A; Zdżalik-Bielecka, D	1
Thol, F	1
Atallah, E; Chiba, S; Hasabou, N; Hosono, N; Kim, HJ; Larson, RA; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Neubauer, A; Onozawa, M; Perl, AE; Podoltsev, NA; Récher, C; Schiller, GJ; Sierra, J; Strickland, S; Tiu, R; Wang, ES; Yoon, SS	1
Bahceci, E; Hill, JE; Levis, MJ; Perl, AE; Rosales, M; Smith, CC	1
Chi, S; Harada, S; Izumiyama, K; Kondo, T; Minami, Y; Miyajima, T; Mori, A; Morioka, M; Ogasawara, R; Saito, M; Yokoyama, E	1
Akashi, K; Egashira, N; Hirota, T; Ieiri, I; Miyamoto, T; Suetsugu, K; Tajima, S; Tsuchiya, Y; Yamauchi, T; Yoshimoto, G; Zhang, M	1
Eşkazan, AE; Nuhoğlu Kantarcı, E	1
Guo, MQ; He, YJ; Huang, YX; Li, KX; Li, YH; Pan, WY; Qiu, DZ; Wu, HY; Yang, DH	1
Lee, T; Mitomi, T; Sugamori, H; Yamagishi, C	1
Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I	1
Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H	1
Aumann, S; Canaani, J; Frisch, A; Ganzel, C; Henig, I; Kugler, E; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M	1
Kataoka, H; Oka, A; Saita, T; Shin, M; Yamada, M	1
Baker, SD; Bhatnagar, B; Blachly, JS; Blaser, BW; Buelow, DR; Eisenmann, ED; Jeon, JY; Orwick, SJ; Pabla, NS; Stromatt, JC	1
Altman, JK; Chou, WC; Esteve, J; Gambacorti-Passerini, C; Gill, SC; Havelange, V; Heuser, M; Hill, JE; Laribi, K; Lee, JH; Liu, S; Minden, MD; Montesinos, P; Naoe, T; Patkowska, E; Philipose, N; Rich, ES; Tiu, RV; Wang, ES; Watson, AM; Wu, R	1
Fu, J; Gu, A; Peng, J; Xu, Y; Yang, B; Zhou, S	1
Barnett, K; Crews, K; Diedrich, JD; Huang, X; Konopleva, M; Li, Z; Pui, CH; Reyes, N; Savic, D; Smart, B; Wang, P; Wei, CL; Xu, B; Yang, JJ; Yang, W; Yeoh, AEJ; Yoshimura, S; Yu, J; Zhang, J; Zhao, X	1
Ciervo, JR; Derkach, A; King, AC; Ranaghan, CP; Stein, ES; Stump, SE; Weis, TM	1
Aoe, M; Fujiwara, K; Ishida, H; Kanamitsu, K; Nodomi, S; Ochi, M; Tamefusa, K; Tatebe, Y; Washio, K	1
Adachi, S; Akazawa, R; Hiramatsu, H; Kamitori, T; Kato, I; Saida, S; Takeshita, S; Takita, J; Tasaka, K; Uchihara, Y; Umeda, K; Usami, A; Yoshioka, Y	1
Asada, N; Ennishi, D; Fujii, K; Fujii, N; Fujiwara, H; Kondo, K; Kondo, T; Maeda, Y; Matsubara, C; Matsumura, A; Matsuoka, KI; Nishimori, H; Terao, T; Ueda, H	1
Braun, T; Cabannes-Hamy, A; Ghez, D; Goldwirt, L; Jacqz-Aigrain, E; Kelly, L; Kohn, M; Lengline, E; Mourah, S; Puissant, A; Raffoux, E; Rousselot, P; Sauvageon, H; Siavellis, J; Vignal, N	1
Kim, H; Kim, IS	1
Fan, G; Gao, J; Liu, G; Luo, P; Qiu, H; Song, X; Wu, J; Yang, Y	1

Reviews

25 review(s) available for pyrazines and gilteritinib

Article	Year
Molecularly targeted therapies for acute myeloid leukemia. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Clinical Trials as Topic; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazines	2015
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Future oncology (London, England), 2018, Volume: 14, Issue:20 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Pyrazines; Recurrence; Research Design	2018
Gilteritinib: First Global Approval. Drugs, 2019, Volume: 79, Issue:3 Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic	2019
New drugs creating new challenges in acute myeloid leukemia. Genes, chromosomes & cancer, 2019, Volume: 58, Issue:12 Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration	2019
Availability of FLT3 inhibitors: how do we use them? Blood, 2019, 08-29, Volume: 134, Issue:9 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine	2019
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Critical reviews in oncology/hematology, 2019, Volume: 141 Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine	2019
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. Cancer, 2019, Sep-15, Volume: 125, Issue:18 Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles	2019
New drugs approved for acute myeloid leukaemia in 2018. British journal of clinical pharmacology, 2019, Volume: 85, Issue:12 Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Disease-Free Survival; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Progression-Free Survival; Pyrazines; Pyridines; Remission Induction; Sulfonamides	2019
Will new agents impact survival in AML? Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:4 Topics: Aniline Compounds; Disease-Free Survival; Drug Approval; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pyrazines; Staurosporine; Survival Rate; United States	2019
The growing landscape of FLT3 inhibition in AML. Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1 Topics: Allografts; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Pyrazines; Staurosporine; Stem Cell Transplantation	2019
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia, 2020, Volume: 34, Issue:3 Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome	2020
Overcoming Resistance to FLT3 Inhibitors in the Treatment of International journal of molecular sciences, 2020, Feb-24, Volume: 21, Issue:4 Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine	2020
AML: New Drugs but New Challenges. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6 Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines	2020
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation. The oncologist, 2020, Volume: 25, Issue:7 Topics: Adult; Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation; Pyrazines	2020
Gilteritinib: potent targeting of FLT3 mutations in AML. Blood advances, 2020, 03-24, Volume: 4, Issue:6 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines	2020
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines	2020
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides	2020
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya journal of medical science, 2020, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines	2020
Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia. Targeted oncology, 2020, Volume: 15, Issue:5 Topics: Aniline Compounds; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines	2020
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine	2020
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles	2020
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells, 2020, 11-17, Volume: 9, Issue:11 Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines; Staurosporine	2020
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Expert opinion on drug safety, 2021, Volume: 20, Issue:7 Topics: Aniline Compounds; Antineoplastic Agents; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Staurosporine	2021
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions. Leukemia research, 2022, Volume: 114 Topics: Adult; Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines	2022
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature. Acta haematologica, 2022, Volume: 145, Issue:5 Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence	2022

Trials

10 trial(s) available for pyrazines and gilteritinib

Article	Year
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. The Lancet. Oncology, 2017, Volume: 18, Issue:8 Topics: Aged; Aniline Compounds; Antineoplastic Agents; Blood Platelets; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Pyrazines; Recurrence; Retreatment	2017
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study. Cancer science, 2018, Volume: 109, Issue:10 Topics: Aged; Aged, 80 and over; Aniline Compounds; Axl Receptor Tyrosine Kinase; Creatine Kinase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Thrombocytopenia; Treatment Outcome	2018
Gilteritinib or Chemotherapy for Relapsed or Refractory The New England journal of medicine, 2019, 10-31, Volume: 381, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Mutation; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis	2019
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics, 2020, Volume: 59, Issue:10 Topics: Aniline Compounds; Drug Interactions; Female; Humans; Male; Protein Kinase Inhibitors; Pyrazines	2020
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies. American journal of hematology, 2020, Volume: 95, Issue:11 Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Disease-Free Survival; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Pyridines; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate	2020
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML. The oncologist, 2021, Volume: 26 Suppl 1 Topics: Aniline Compounds; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines	2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-01, Volume: 27, Issue:13 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Posterior Leukoencephalopathy Syndrome; Pyrazines	2021
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood, 2022, 06-09, Volume: 139, Issue:23 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence	2022
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood advances, 2022, 04-12, Volume: 6, Issue:7 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines	2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood, 2022, 10-27, Volume: 140, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Pyrazines	2022

Other Studies

66 other study(ies) available for pyrazines and gilteritinib

Article	Year
Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients. Future oncology (London, England), 2015, Volume: 11, Issue:18 Topics: Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Treatment Outcome	2015
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood, 2017, 01-12, Volume: 129, Issue:2 Topics: Aniline Compounds; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines	2017
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investigational new drugs, 2017, Volume: 35, Issue:5 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays	2017
First new drug approval for AML in 15 years. Nature biotechnology, 2017, 08-08, Volume: 35, Issue:8 Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines	2017
Closing in on targeted therapy for acute myeloid leukaemia. The Lancet. Haematology, 2019, Volume: 6, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine	2019
Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core. Bioorganic & medicinal chemistry letters, 2019, 03-15, Volume: 29, Issue:6 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Drug Discovery; Mice; Molecular Structure; Protein Kinase Inhibitors; Pyrazines; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases	2019
Gilteritinib induces differentiation in relapsed and refractory Blood advances, 2019, 05-28, Volume: 3, Issue:10 Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Recurrence	2019
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British journal of haematology, 2019, Volume: 187, Issue:4 Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines	2019
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 11-15, Volume: 25, Issue:22 Topics: Aniline Compounds; Animals; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides; Xenograft Model Antitumor Assays	2019
Gilteritinib Changes AML Landscape. Oncology (Williston Park, N.Y.), 2019, 08-23, Volume: 33, Issue:8 Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; Drug Approval; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome	2019
Improving Response to FLT3 Inhibitors-BCL2 the Rescue? Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 11-15, Volume: 25, Issue:22 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine	2019
Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after co Geriatrics & gerontology international, 2019, Volume: 19, Issue:10 Topics: Aged; Aniline Compounds; Antineoplastic Agents; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Pyrazines	2019
Gilteritinib improves outcomes in AML. Nature reviews. Clinical oncology, 2020, Volume: 17, Issue:2 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines	2020
How I treat acute myeloid leukemia in the era of new drugs. Blood, 2020, 01-09, Volume: 135, Issue:2 Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines	2020
Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. Blood advances, 2019, 11-26, Volume: 3, Issue:22 Topics: Aniline Compounds; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Pyrazines	2019
Gilteritinib induces PUMA-dependent apoptotic cell death via AKT/GSK-3β/NF-κB pathway in colorectal cancer cells. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:3 Topics: Aniline Compounds; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Death; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; Female; Glycogen Synthase Kinase 3 beta; HCT116 Cells; HEK293 Cells; Humans; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays	2020
Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib. Marine drugs, 2020, Jan-16, Volume: 18, Issue:1 Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aquatic Organisms; Autophagy; Biological Products; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Signal Transduction; U937 Cells; Zebrafish	2020
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:5 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase	2020
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood advances, 2020, 02-11, Volume: 4, Issue:3 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Mutation; Protein Kinase Inhibitors; Pyrazines	2020
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor. JAMA ophthalmology, 2020, 04-01, Volume: 138, Issue:4 Topics: Administration, Oral; Aniline Compounds; Ciliary Body; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Uveal Neoplasms; Visual Acuity	2020
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. International journal of hematology, 2020, Volume: 112, Issue:2 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyrazines; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome	2020
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. International journal of hematology, 2020, Volume: 112, Issue:2 Topics: Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence; Remission Induction; Reoperation; Tandem Repeat Sequences; Tissue Donors; Treatment Outcome	2020
Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia. Leukemia & lymphoma, 2020, Volume: 61, Issue:8 Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Receptors, Aryl Hydrocarbon	2020
[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:4 Topics: Aniline Compounds; Child; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines; Recurrence	2020
An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study. Drug design, development and therapy, 2020, Volume: 14 Topics: Administration, Oral; Aniline Compounds; Animals; Chromatography, High Pressure Liquid; Drug Interactions; Fluconazole; Itraconazole; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry	2020
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19. British journal of haematology, 2020, Volume: 190, Issue:4 Topics: Adult; Aniline Compounds; COVID-19; COVID-19 Drug Treatment; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Remission Induction; SARS-CoV-2	2020
Acute Macular Neuroretinopathy Associated With an Oral FLT3 Inhibitor. JAMA ophthalmology, 2020, 10-01, Volume: 138, Issue:10 Topics: Administration, Oral; Adult; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Macula Lutea; Pyrazines; Tomography, Optical Coherence; White Dot Syndromes	2020
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a Future oncology (London, England), 2021, Volume: 17, Issue:2 Topics: Aniline Compounds; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrazines; Recurrence; Retreatment; Treatment Outcome	2021
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. Journal of hematology & oncology, 2020, 10-19, Volume: 13, Issue:1 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; CRISPR-Cas Systems; Female; fms-Like Tyrosine Kinase 3; Gene Knockout Techniques; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides	2020
Gilteritinib administration in a hemodialysis patient. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:5 Topics: Aged; Aniline Compounds; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Renal Dialysis	2021
Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:4 Topics: Adult; Aniline Compounds; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines	2021
[Pharmacological and clinical profile of gilteritinib (Xospata Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2021, Volume: 156, Issue:1 Topics: Adult; Aniline Compounds; Animals; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Mice; Mutation; Pyrazines; Tablets; United States	2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature communications, 2021, 02-24, Volume: 12, Issue:1 Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases	2021
Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Adolescent; Aniline Compounds; Biopsy; Blast Crisis; Bone Marrow; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Monocytes; Protein Kinase Inhibitors; Pyrazines; Radiography, Thoracic; Tandem Repeat Sequences	2021
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance. American journal of hematology, 2021, 07-01, Volume: 96, Issue:7 Topics: Aniline Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Models, Molecular; Mutation; Protein Kinase Inhibitors; Pyrazines	2021
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer. Annals of hematology, 2022, Volume: 101, Issue:2 Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines	2022
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib. Leukemia research, 2021, Volume: 108 Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antifungal Agents; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Triazoles; Young Adult	2021
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood cancer journal, 2021, 06-07, Volume: 11, Issue:6 Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, Transgenic; Morpholines; Pyrazines; Pyrimidines; THP-1 Cells; Xenograft Model Antitumor Assays	2021
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer cell, 2021, 07-12, Volume: 39, Issue:7 Topics: Aniline Compounds; Aurora Kinase B; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exome; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Metabolome; Protein Kinase Inhibitors; Proteome; Pyrazines; Tumor Cells, Cultured; Tumor Microenvironment	2021
Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report. Pediatric blood & cancer, 2021, Volume: 68, Issue:11 Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Pore Complex Proteins; Peripheral Blood Stem Cell Transplantation; Pyrazines	2021
Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, Aug-01, Volume: 1179 Topics: Aniline Compounds; Animals; Chromatography, Liquid; Female; HEK293 Cells; Humans; Limit of Detection; Linear Models; Mice; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry	2021
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21 Topics: Aniline Compounds; Axl Receptor Tyrosine Kinase; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases	2021
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib. Chemotherapy, 2021, Volume: 66, Issue:4 Topics: Aniline Compounds; Bone Marrow; Brain; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome	2021
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood advances, 2021, 12-14, Volume: 5, Issue:23 Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines	2021
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia. Blood advances, 2021, 12-14, Volume: 5, Issue:23 Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Up-Regulation	2021
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. Leukemia & lymphoma, 2022, Volume: 63, Issue:3 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Salvage Therapy	2022
Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner. Molecular cancer research : MCR, 2022, Mar-01, Volume: 20, Issue:3 Topics: Aniline Compounds; Autophagy; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Proliferation; Humans; Lysosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Transfection; Triazoles	2022
What to use to treat AML: the role of emerging therapies. Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1 Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines	2021
[Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:1 Topics: Aged; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines	2022
Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation-Positive Acute Myelogenous Leukemia. Therapeutic drug monitoring, 2022, 08-01, Volume: 44, Issue:4 Topics: Aniline Compounds; Chromatography, High Pressure Liquid; Chromatography, Liquid; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Mutation; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry	2022
A novel approach for relapsed/refractory FLT3 Molecular cancer, 2022, 03-04, Volume: 21, Issue:1 Topics: Aniline Compounds; Animals; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; NF-kappa B p52 Subunit; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes	2022
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan. Japanese journal of clinical oncology, 2022, 07-08, Volume: 52, Issue:7 Topics: Aniline Compounds; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Mutation; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrazines	2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood cancer journal, 2022, 05-30, Volume: 12, Issue:5 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine	2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Annals of hematology, 2022, Volume: 101, Issue:9 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines	2022
An Indirect Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Brigatinib and Gilteritinib Using a Specific Polyclonal Antibody. Biological & pharmaceutical bulletin, 2022, Volume: 45, Issue:7 Topics: Aniline Compounds; Animals; Antibodies; Enzyme-Linked Immunosorbent Assay; Mice; Organophosphorus Compounds; Pyrazines; Pyrimidines; Rats	2022
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors. Blood advances, 2022, 09-13, Volume: 6, Issue:17 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein-Tyrosine Kinases; Pyrazines; Tumor Microenvironment	2022
Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy. Journal of molecular modeling, 2022, Aug-06, Volume: 28, Issue:9 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines	2022
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nature communications, 2022, 09-14, Volume: 13, Issue:1 Topics: Aniline Compounds; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Gene Fusion; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Trans-Activators; Transcription Factors	2022
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis. Leukemia research, 2022, Volume: 122 Topics: Aniline Compounds; Azoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines	2022
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155. Blood advances, 2022, 11-22, Volume: 6, Issue:22 Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines	2022
Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication. Pediatric blood & cancer, 2023, Volume: 70, Issue:4 Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines	2023
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib. Pediatric blood & cancer, 2023, Volume: 70, Issue:5 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence	2023
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML. Blood advances, 2023, 03-14, Volume: 7, Issue:5 Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines	2023
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia Haematologica, 2023, 09-01, Volume: 108, Issue:9 Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Treatment Outcome	2023
Emergence of Annals of laboratory medicine, 2023, 07-01, Volume: 43, Issue:4 Topics: Aniline Compounds; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Pyrazines	2023
Gilteritinib-induced severe immune-related enteritis: a possible case report. Anti-cancer drugs, 2023, 08-01, Volume: 34, Issue:7 Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines	2023